Sunshine Biopharma Files Definitive Proxy Statement
Ticker: SBFMW · Form: DEF 14A · Filed: Oct 17, 2024 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma, Inc (SBFMW) |
| Form Type | DEF 14A |
| Filed Date | Oct 17, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, sec-filing
TL;DR
Sunshine Biopharma filed its DEF 14A proxy statement for the 2024 fiscal year. Standard shareholder info.
AI Summary
Sunshine Biopharma, Inc. filed a Definitive Proxy Statement (DEF 14A) on October 17, 2024, for its fiscal year ending December 31, 2024. The company, previously known as Mountain West Business Solutions, Inc., is based in Fort Lauderdale, Florida, and operates in the pharmaceutical preparations industry. This filing is a standard procedural document related to shareholder matters.
Why It Matters
This filing provides shareholders with essential information regarding upcoming annual meetings, voting procedures, and company governance, which is crucial for informed participation in corporate decisions.
Risk Assessment
Risk Level: low — This filing is a routine administrative document and does not contain new financial performance data or strategic changes that would inherently increase risk.
Key Numbers
- 001-41282 — SEC File Number (Identifies the company's filings with the SEC.)
Key Players & Entities
- Sunshine Biopharma, Inc. (company) — Registrant
- Mountain West Business Solutions, Inc. (company) — Former Company Name
- 20241017 (date) — Filing Date
- 20241210 (date) — Fiscal Year End
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is filed by a company to solicit proxies from shareholders for an upcoming annual or special meeting. It contains information about the meeting, matters to be voted on, and details about the company's board of directors and executive compensation.
When is Sunshine Biopharma's fiscal year end?
Sunshine Biopharma's fiscal year ends on December 31, as indicated by the 'CONFORMED PERIOD OF REPORT: 20241210'.
What was Sunshine Biopharma's former name?
Sunshine Biopharma was formerly known as Mountain West Business Solutions, Inc., with name changes recorded on October 30, 2007, and June 7, 2007.
Where is Sunshine Biopharma located?
Sunshine Biopharma's business and mailing address is 333 LAS OLAS WAY, CU4 SUITE 433, FORT LAUDERDALE, FL 33301.
What is the SIC code for Sunshine Biopharma?
The Standard Industrial Classification (SIC) code for Sunshine Biopharma is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,692 words · 19 min read · ~16 pages · Grade level 12 · Accepted 2024-10-17 16:05:07
Filing Documents
- sunshine_def14a.htm (DEF 14A) — 204KB
- 0001683168-24-007196.txt ( ) — 206KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 17 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 19 2023 ANNUAL REPORT ON FORM 10-K 19 OTHER MATTERS 19 STOCKHOLDER PROPOSALS FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS 20 SUNSHINE BIOPHARMA INC. 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale, FL 33301 October 17, 2024 To our Stockholders: On behalf of our Board of Directors, I cordially invite you to attend our 2024 Annual Meeting of Stockholders on December 10, 2024, at 10:00 a.m., Eastern Time, which shall be held online. During the meeting we will discuss the items of business described in the accompanying Notice of Annual Meeting and Proxy Statement, update you on important developments in our business and respond to any questions that you may have about us. We are furnishing proxy materials to some of our shareholders via the Internet by mailing a Notice of Internet Availability of Proxy Materials instead of mailing or emailing copies of those materials. The Notice of Internet Availability of Proxy Materials directs shareholders to a website where they can access our proxy materials, including our proxy statement and our annual report, and view instructions on how to vote via the Internet, mobile device, or by telephone. If you received a Notice of Internet Availability of Proxy Materials and would prefer to receive a paper copy of our proxy materials, please follow the instructions included in the Notice of Internet Availability of Proxy Materials. I look forward to your participation at the meeting. Yours truly, Dr. Steve N. Slilaty Chairperson of the Board of Directors i SUNSHINE BIOPHARMA INC. 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale, FL 33301 NOTICE OF 2024 ANNUAL MEETING OF SHAREHOLDERS TO BE HELD TUESDAY, DECEMBER 10, 2024 Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held Tuesday, December 10, 2024 The Notice of 2024 Annual Meeting, Proxy Statement and our Annual Report on